Program
lifileucel
Also written as “LN-145”, “Lifileucel” and “Autologous Tumor Infiltrating Lymphocytes”.
Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Liposarcoma · Uterine Cervical Neoplasms · Endometrial Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Iovance Biotherapeutics | 105 open or running | phase 3since Feb 6, 2023 | Feb 3, 2015 | Dec 2027phase 2 · NCT07288203 |
| Shanghai Juncell Therapeutics | 22 open or running | phase 2since Apr 24, 2026 | Jun 18, 2024 | Jan 1, 2027phase 1 · NCT06473961 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 3, 2015First study: phase 2 study in MelanomaNew to Iovance BiotherapeuticsIovance Biotherapeutics · NCT02360579 · 220 enrolled · United States, France, Germany and more
- Mar 14, 20172 phase 2 studiesIovance Biotherapeutics · NCT03083873, NCT03108495
- Jan 14, 2018Phase 2 study in Carcinoma, Non-Small-Cell LungIovance Biotherapeutics · NCT03419559 · United States
- Aug 22, 2018Phase 2 study in MelanomaIovance Biotherapeutics · NCT03645928 · 225 enrolled · United States, Canada, Germany and more
- Oct 21, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungIovance Biotherapeutics · NCT04614103 · 170 planned · United States, Australia, Canada and more
- Feb 6, 2023Phase 3 study in MelanomaIovance Biotherapeutics · NCT05727904 · 670 planned · United States, Australia, Belgium and more
- Jun 18, 2024Shanghai Juncell Therapeutics's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Shanghai Juncell TherapeuticsShanghai Juncell Therapeutics · NCT06473961 · 20 planned · China
- Jun 25, 2024Phase 2 study in Endometrial NeoplasmsIovance Biotherapeutics · NCT06481592 · 60 planned · United States
- Dec 9, 2025Phase 2 study in MelanomaIovance Biotherapeutics · NCT07288203 · 24 enrolled · United States, Australia, Canada and more
- Apr 24, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedShanghai Juncell Therapeutics · NCT07560111 · 28 planned · China
- Jul 28, 2026Phase 2 study in SarcomaIovance Biotherapeutics · NCT07741877 · 80 planned · United States
Ahead
- Jan 1, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungShanghai Juncell Therapeutics · NCT06473961
- Jun 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungShanghai Juncell Therapeutics · NCT07560111
- Dec 2027Primary completion: phase 2 study in MelanomaIovance Biotherapeutics · NCT07288203
- Mar 1, 2028Primary completion: phase 3 study in MelanomaIovance Biotherapeutics · NCT05727904
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07741877Sarcoma · United States | 2 | Recruiting | Iovance Biotherapeutics | Sep 1, 2033 | 80 |
| NCT07560111Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Shanghai Juncell Therapeutics | Jun 1, 2027 | 28 |
| NCT07288203Melanoma · United States, Australia, Canada and more | 2 | Active, not recruiting | Iovance Biotherapeutics | Dec 2027 | 24 |
| NCT06481592Endometrial Neoplasms · United States | 2 | Recruiting | Iovance Biotherapeutics | May 2028 | 60 |
| NCT06473961Carcinoma, Non-Small-Cell Lung · China | 1 | Recruiting | Shanghai Juncell Therapeutics | Jan 1, 2027 | 20 |
| NCT05727904Melanoma · United States, Australia, Belgium and more | 3 | Recruiting | Iovance Biotherapeutics | Mar 1, 2028 | 670 |
| NCT04614103Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Recruiting | Iovance Biotherapeutics | Dec 2030 | 170 |
| NCT03645928Melanoma · United States, Canada, Germany and more | 2 | Terminated | Iovance Biotherapeutics | Feb 20, 2026 | 225 |
| NCT03419559Carcinoma, Non-Small-Cell Lung · United States | 2 | Withdrawn | Iovance Biotherapeutics | Dec 2021 | 0 |
| NCT03108495Uterine Cervical Neoplasms · United States, France, Germany and more | 2 | Terminated | Iovance Biotherapeutics | Aug 22, 2025 | 210 |
| NCT03083873Squamous Cell Carcinoma of Head and Neck · United States | 2 | Completed | Iovance Biotherapeutics | Aug 8, 2022 | 64 |
| NCT02360579Melanoma · United States, France, Germany and more | 2 | Completed | Iovance Biotherapeutics | Oct 24, 2024 | 220 |
How it is read
Names in the registry
- “LN-145”, 6 entries
- “Lifileucel”, 5 entries
- “Autologous Tumor Infiltrating Lymphocytes”, 2 entries
- “LN-145 + pembrolizumab”, 1 entry
- “Lifileucel plus Pembrolizumab”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 4 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Liposarcoma, 1 study
- Uterine Cervical Neoplasms, 1 study
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.